⌕
Pharming Group · PHAR · Nasdaq
Tenet 41 · Weak
Compare
$12.59−0.08%At closeTenet 41 · Weak
$12.59−0.01 (−0.08%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Pharming Group (PHAR) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is PHAR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 11, 2026 · 02:00 ETCOMPANY'S OWN WORDS
Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London

Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London on Wednesday Nov. 18 at 9:30 am GMT. Webcast will be available…

PHAR −0.1% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 01:00 ET
MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.

MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. Approval extends existing U.K. indication.…

PHAR −0.1% todayRead at source ↗
● Fool - Investing NewsNov 4, 2026 · 17:00 ET
Pharming: 3 Key Takeaways for Long-Term Investors

A rare-disease player with a stabilized core product is now targeting a market 26 times larger, fueled by cash generation that needs no external financing.…

PHAR −0.1% todayRead at source ↗
● Seeking AlphaOct 27, 2026 · 12:59 ET
Pharming Group N.V. (PHAR) Q3 2026 Earnings Call Transcript

Pharming Group N.V. ( PHAR ) Q3 2026 Earnings Call October 27, 2026 8:30 AM EDT Company Participants Kenneth Lynard - CFO & Co-Chief Executive Officer Leverne Marsh - Co-CEO & Chief Commercial Officer Anurag Relan - Chie…

PHAR −0.1% todayRead at source ↗
● MarketBeatOct 27, 2026 · 11:07 ET
Pharming Group Q3 Earnings Call Highlights

Pharming Group NASDAQ: PHAR reported third-quarter revenue growth of 21% to $117.6 million, supported by higher sales of its RUCONEST hereditary angioedema treatment and Joenja therapy for activated phosphoinositide 3-ki…

PHAR −0.1% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 02:00 ETCOMPANY'S OWN WORDS
Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations RUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025,…

PHAR −0.1% todayRead at source ↗
● GlobeNewsWireOct 22, 2026 · 01:00 ETCOMPANY'S OWN WORDS
Pharming Group announces third quarter 2026 revenues above market expectations

Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025 Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter…

PHAR −0.1% todayRead at source ↗
● GlobeNewsWireOct 14, 2026 · 02:00 ETCOMPANY'S OWN WORDS
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation Leniolisib was well-tolerated, with benefits obs…

PHAR −0.1% todayRead at source ↗
● Seeking AlphaSep 30, 2026 · 08:16 ET
Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes

RUCONEST is Pharming Group's main revenue source today. This asset has already shown a sequential sales rebound that makes me more optimistic. However, RUCONEST still has oral competition that could make stabilizing that…

PHAR −0.1% todayRead at source ↗
● GlobeNewsWireSep 29, 2026 · 01:00 ETCOMPANY'S OWN WORDS
Pharming announces CEO transition

Leiden, the Netherlands, September 29, 2026 : Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and…

PHAR −0.1% todayRead at source ↗
● GlobeNewsWireSep 25, 2026 · 10:30 ETCOMPANY'S OWN WORDS
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

If approved, J oenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more Decision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least…

PHAR −0.1% todayRead at source ↗
● GlobeNewsWireSep 22, 2026 · 01:00 ETCOMPANY'S OWN WORDS
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results fro…

PHAR −0.1% todayRead at source ↗
● Defense WorldSep 21, 2026 · 07:05 ET
MAC Alpha Capital Management LP Makes New $29.84 Million Investment in Pharming Group N.V. Sponsored ADR $PHAR

MAC Alpha Capital Management LP acquired a new position in Pharming Group N.V. Sponsored ADR (NASDAQ: PHAR) during a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange…

PHAR −0.1% todayRead at source ↗
● GlobeNewsWireSep 11, 2026 · 14:00 ET
FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.

FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg Newly approved Joenja doses are expected to be availa…

PHAR −0.1% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA6−4.1%
BRK-A5−0.3%
ABR4−8.6%
AMD3−5.5%

Article counts from the last market-wide feed page, across every symbol we track and not just PHAR · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.